ORCID as entered in ROS
https://orcid.org/0000-0003-3090-795X
Select Publications
Conference Papers
, 2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at
, 2011, 'A Novel Approach to the Emerging and Frequent Problem of Sustained Long-term Oxaliplatin-induced Neurotoxicity', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S436 - S436, presented at
, 2011, 'Oxaliplatin-induced Neurotoxicity - Comparing Four Methods of Assessment', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S234 - S234, presented at
, 2011, 'Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5026
, 2011, 'Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.tps241
, 2011, 'Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5003
, 2011, 'Prospective study of breast cancer risk in mutation-negative women from BRCA1 or BRCA2 mutation-positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1516
, 2011, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1500
, 2011, '2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference', in International Journal of Gynecological Cancer, pp. 750 - 755, http://dx.doi.org/10.1097/IGC.0b013e31821b2568
, 2011, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.7_suppl.227
, 2010, 'Implementation and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, presented at
, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Sydney Australia, presented at
, 2010, 'Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.5105
, 2010, 'Pathophysiology of paclitaxel-induced neurotoxicity', in Small D (ed.), Australian Neurosciences Society Annual Scientific Meeting 2010, ANS, Sydney, pp. 160 - 160, presented at
, 2010, 'Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 53 - 60, presented at
, 2010, 'What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study', in Journal of Clinical Oncology, American Society of Clinical Oncology, United States, pp. 93s
, 2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
, 2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at
, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2072 - 2072, http://dx.doi.org/10.1158/0008-5472.sabcs-2072
, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study', in Cancer research, American Association Cancer Research, Philadelphia, PA, pp. 178S - 178S
, 2008, 'PAZOPANIB (GW786034) IS ACTIVE IN WOMEN WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PERITONEAL CANCERS: RESULTS OF A PHASE II STUDY', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWEDEN, Stockholm, pp. 211 - 211, presented at
, 2008, 'Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.1528
, 2008, 'Early detection of oxaliplatin-induced neurotoxicity: Getting it before it hurts', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.15015
, 2008, 'Medical Oncology Group of Australia (MOGA)/Novartis cancer achievement award', in Cancer Forum, pp. 27 - 31
, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S36 - S37, presented at
, 2007, 'Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043701341&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2007, 'Breast cancer and fertility: Making hard choices easier - The development and evaluation of fertility-related decision aid for young women with early breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S15 - S16, presented at
, 2006, 'Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, GA, Atlanta, pp. 53S - 53S, presented at
, 2005, 'Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens', in Annals of Oncology, http://dx.doi.org/10.1093/annonc/mdi962
, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, pp. 266S - 266S, presented at
, 2005, 'A phase II trial of Paclitaxel in previously treated patients with metastatic breast cancer.', in Medical Journal of Australia, Australasian Med Publishing Company Ltd, Sydney, NSW, Australia, pp. 520 - 523, presented at
, 2004, 'What survival benefits do pre-menopausal early breast cancer patients consider necessary to make endocrine therapy worthwhile?', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S40 - S41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223957800084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 459S - 459S, presented at
, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 845S - 845S, presented at
, 2003, 'The fertility and menopause related information needs of younger women with a diagnosis of breast cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S125 - S125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400153&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2002, 'Steroid hormone receptor expression in heriditary and sporadic ovarian cancers', in Proceedings of the American Association for Cancer Research, American Association Cancer Research, Philadelphia, PA, USA, pp. 6 - 6, presented at
, 1999, 'Australian Jewish women's experiences with a breast cancer gene testing program as part of the co-operative family registry for breast cancer studies (CFR-BCS).', in AMERICAN JOURNAL OF HUMAN GENETICS, UNIV CHICAGO PRESS, pp. A191 - A191, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000082879801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1999, 'Enhancement of cisplatin cytotoxicity by caffeine does not correlate with abrogation of G2 arrest.', in BRITISH JOURNAL OF CANCER, CHURCHILL LIVINGSTONE, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081955000151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1998, 'Candidate regions for testicular cancer susceptibility genes: The International Testicular Cancer Linkage Consortium', in APMIS, pp. 64 - 72, http://dx.doi.org/10.1111/j.1699-0463.1998.tb01320.x
, 1997, 'Activity of Gemcitabine in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 538 - 538, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997XX83000533&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1997, 'Candidate regions for testicular cancer susceptibility genes', in APMIS, WILEY, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, pp. 64 - 70, presented at
, 1995, 'Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 1084 - 1084, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995TH91901079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 1983, 'FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT IN OVARIAN-CANCER', in CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, BLACKWELL SCIENCE, pp. 489 - 489, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RB75800115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Filter by type
https://orcid.org/0000-0003-3090-795X